Stockscreener 앱 받기
1.26
3.08%
-0.04
시간 외 거래:
1.20
-0.06
-4.76%
전일 마감가:
$1.30
열려 있는:
$1.3
하루 거래량:
143.51K
Relative Volume:
0.42
시가총액:
$32.97M
수익:
-
순이익/손실:
$-13.76M
주가수익비율:
-1.3548
EPS:
-0.93
순현금흐름:
-
1주 성능:
+16.67%
1개월 성능:
-40.00%
6개월 성능:
+8.62%
1년 성능:
+100.64%
1일 변동 폭
$1.22
$1.3299
1주일 범위
$1.06
$1.52
52주 변동 폭
$0.6355
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
NRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.26 | 32.97M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
Should you hold or exit NeuroSense Therapeutics Ltd. nowReal-Time Investment Picks with Accuracy - Newser
Why NeuroSense Therapeutics Ltd. is moving todayFree Stock Screener With Smart Filters - Newser
Applying chart zones and confluence areas to NeuroSense Therapeutics Ltd. Equity WarrantFree Secure Return Focused Investment Plan - Newser
What institutional flow reveals about NeuroSense Therapeutics Ltd. Equity WarrantFree Community Verified Stock Suggestions - Newser
What indicators show strength in NeuroSense Therapeutics Ltd.Fundamental Forecast for Undervalued Stocks - Newser
Chart based exit strategy for NeuroSense Therapeutics Ltd.Weekly Outlook for Short Term Investors - Newser
Detecting price anomalies in NeuroSense Therapeutics Ltd. Equity Warrant with AIAlgorithmic Prediction of Market Breakouts - Newser
How hedge fund analytics apply to NeuroSense Therapeutics Ltd. stockSmart Money Strategy for Growth Stocks - Newser
NeuroSense Therapeutics Ltd. Equity Warrant Company Revenue and Profit Trends: A Deep DiveSecure Entry Point Finder with Analysis - Newser
Published on: 2025-08-08 18:28:49 - Newser
Can NeuroSense Therapeutics Ltd. Equity Warrant hit a new high this monthEarnings Based Stock Performance Forecast - Newser
Why NeuroSense Therapeutics Ltd. stock attracts strong analyst attentionFree Investment Strategy With Low Risk - Newser
Maxim Group Analyst Maintains Hold Rating on Neurosense Therapeutics Ltd. - AInvest
What Fibonacci levels say about NeuroSense Therapeutics Ltd. reboundReal-Time AI Generated Market Forecast - Newser
Should you wait for a breakout in NeuroSense Therapeutics Ltd.Early Buy Opportunity with Chart Triggers - Newser
What is NeuroSense Therapeutics Ltd. company’s growth strategyAchieve breakthrough investment performance - Jammu Links News
What are analysts’ price targets for NeuroSense Therapeutics Ltd. in the next 12 monthsInvest confidently with professional market insights - Jammu Links News
What institutional investors are buying NeuroSense Therapeutics Ltd. Equity Warrant stockAchieve breakthrough growth with proven strategies - Jammu Links News
What institutional investors are buying NeuroSense Therapeutics Ltd. stockDynamic growth stocks - Jammu Links News
How volatile is NeuroSense Therapeutics Ltd. stock compared to the marketConsistent wealth multiplication - Jammu Links News
How strong is NeuroSense Therapeutics Ltd. company’s balance sheetFree Consultation - Jammu Links News
What are NeuroSense Therapeutics Ltd. company’s key revenue driversAccelerate your capital gains today - Jammu Links News
How does NeuroSense Therapeutics Ltd. Equity Warrant generate profit in a changing economyBreakthrough stock performance - Jammu Links News
What are the technical indicators suggesting about NeuroSense Therapeutics Ltd. Equity WarrantConsistently profitable trades - Jammu Links News
What analysts say about NeuroSense Therapeutics Ltd. stockInvest confidently with actionable market data - Jammu Links News
NeuroSense Therapeutics Ltd. Equity Warrant Stock Analysis and ForecastTremendous financial leverage - Jammu Links News
What are the latest earnings results for NeuroSense Therapeutics Ltd. Equity WarrantDynamic portfolio growth - Jammu Links News
How does NeuroSense Therapeutics Ltd. Equity Warrant compare to its industry peersBreakthrough profit margins - Jammu Links News
When is NeuroSense Therapeutics Ltd. Equity Warrant stock expected to show significant growthAchieve fast wealth growth with smart picks - Jammu Links News
NeuroSense Therapeutics Ltd. Stock Analysis and ForecastNavigate market volatility with smart strategies - Jammu Links News
How does NeuroSense Therapeutics Ltd. compare to its industry peersBuild wealth faster with disciplined trading - Jammu Links News
How volatile is NeuroSense Therapeutics Ltd. Equity Warrant stock compared to the marketBuild a diversified portfolio for risk management - Jammu Links News
What is NeuroSense Therapeutics Ltd. Equity Warrant company’s growth strategyGet exclusive market analysis for investors - Jammu Links News
Is NeuroSense Therapeutics Ltd. a good long term investmentBreakthrough capital growth - Jammu Links News
Published on: 2025-08-03 03:33:27 - Jammu Links News
What makes NeuroSense Therapeutics Ltd. Equity Warrant stock price move sharplyGrow your wealth with proven stock picks - Jammu Links News
How many analysts rate NeuroSense Therapeutics Ltd. Equity Warrant as a “Buy”Stay ahead with daily expert stock picks - Jammu Links News
Volume Surge May Signal Institutional Interest in NeuroSense Therapeutics Ltd. Equity WarrantWeekly Stock Watch With Growth Focus Expanded - beatles.ru
Is NeuroSense Therapeutics Ltd. a growth stock or a value stockFree Stock Target Finder With Proven Results - Jammu Links News
NeuroSense Therapeutics: Navigating the ALS Treatment Frontier Amid Financial Constraints - AInvest
Neurosense Therapeutics shares rise 5.56% after-hours following a positive business update and progress report. - AInvest
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 - MarketScreener
NeuroSense Therapeutics Advances ALS Treatment with Phase 3 Trial Plans - TipRanks
Sector Rotation Brings NeuroSense Therapeutics Ltd. Into FocusVerified Signal From Chart Patterns Detected - metal.it
NeuroSense's ALS Drug Achieves Breakthrough: 40% Slower Decline, 74% Better Survival as Phase 3 Nears - Stock Titan
Does NeuroSense Therapeutics Ltd. stock perform well during market downturnsExpert Picks Signals To Watch Now - Jammu Links News
NeuroSense Therapeutics Ltd. Equity Warrant stock prediction for this weekEntry Zone Strategy for Consistent Profit Shared - metal.it
What is the risk reward ratio of investing in NeuroSense Therapeutics Ltd. Equity Warrant stockPre Market Forecasts That Work - Jammu Links News
Neurosense Therapeutics Ltd (NRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):